You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
冠昊生物(300238.SZ):2022年度預虧3億元-3.6億元
格隆匯 01-17 16:26

格隆匯1月17日丨冠昊生物(300238.SZ)公佈2022年年度業績預吿,公司預計實現歸屬於上市公司股東的淨利潤為虧損3億元-3.6億元;預計實現扣除非經常性損益後的淨利潤為虧損3.2億元-3.8億元。

報吿期內,公司業績虧損,主要影響因素有以下幾個方面:

1.公司收購的子公司珠海市祥樂醫療器械有限公司(以下簡稱“珠海祥樂”)與Aaren Scientific Inc.簽訂的國內獨家經銷商的經銷協議提前終止。受此影響,珠海祥樂本報吿期收入較上年同期降幅超過70%。根據《企業會計準則》和公司會計政策的相關規定,公司對因併購珠海祥樂股權形成的商譽進行了減值測試,對珠海祥樂的商譽全額計提資產減值損失,金額為2.14億元。對珠海祥樂的庫存商品進行了跌價測算,計提存貨跌價準備約7000萬元。

2.公司投資的聯營及合營企業因疫情、經營等原因,經營效果低於公司投資預期,管理層根據被投資企業現狀及預期發展等進行減值測算,減值總計約4500萬元。

3.公司預計2022年度非經常性損益對歸屬於上市公司股東的淨利潤的影響金額約2000萬元(2021年同期非經常性損益對淨利潤的影響金額為2254.11萬元)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account